Categories: News

Exclusively Sponsored by Sinopec’s Aipao Racing Fuel, the 2026 China Taklimakan Rally Kicks Off in Urumqi

URUMQI, China, May 18, 2026 /PRNewswire/ — With the command to start, 152 vehicles and nearly 300 competitors of 74 teams from around the world embarked on a 7,500-kilometer extreme journey as the 2026 China Taklimakan Rally, exclusively sponsored by the Aipao racing fuel brand by China Petroleum & Chemical Corporation (HKG: 0386, “Sinopec”), officially kicked off on May 16 in Urumqi, Xinjiang Uygur Autonomous Region, China.

- Advertisement -

Spanning 17 days, this year’s rally sets a new distance record as it traverses northern and southern Xinjiang. The route begins in Urumqi, passes through Turpan, Bayingolin Mongol Autonomous Prefecture, Hotan, and Kashi, and concludes in Aksu. Competitors will tackle extreme terrain, including the vast Taklimakan Desert and the rugged canyons of the Tianshan Mountains.

- Advertisement -

Aipao 103, China’s first domestically developed racing fuel by Sinopec, is the official fuel for the China Taklimakan Rally. With an RON exceeding 103, the fuel offers four core advantages of anti-knock performance, environmental friendliness, high combustion efficiency, and safety. Designed for extreme racing conditions, it fills a long-standing gap in China’s high-performance racing fuel market and marks a major milestone for Sinopec and China’s refining industry toward world-class standards.

- Advertisement -

Chen Yanbin, director and senior vice president of Sinopec, highlighted Xinjiang’s strategic role as the core area of the Silk Road Economic Belt and the rally’s status as a world-class off-road event.

- Advertisement -

“Guided by our commitment to ‘Clean Energy, Better Life,’ Sinopec continues to sponsor the rally through the Aipao brand, delivering comprehensive fuel assurance for China’s motorsport,” said Chen. “Going forward, we will deepen the integration of energy, sports, and tourism to drive high-quality growth in Xinjiang and contribute to the Belt and Road Initiative.”

- Advertisement -

To ensure seamless operations, Sinopec has comprehensively upgraded its energy support system, deploying over 40 mobile refueling points along the route. An innovative “fixed + mobile” dual-mode strategy guarantees precise, timely, and safe fuel supply—even in the most remote desert sections.

- Advertisement -

Since its launch in 2015, Aipao has earned the trust of over 10 million users with its world-class cleanliness and performance. The brand, valued at more than 18 billion yuan (approx. USD 2.64 billion), continues to lead China’s fuel market in influence.

- Advertisement -

For more information, please visit http://www.sinopec.com/listco/en/.

- Advertisement -

Photo – https://mma.prnewswire.com/media/2981807/image1.jpg
Logo – https://mma.prnewswire.com/media/960416/SINOPEC_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/exclusively-sponsored-by-sinopecs-aipao-racing-fuel-the-2026-china-taklimakan-rally-kicks-off-in-urumqi-302774370.html

- Advertisement -

Recent Posts

Lumissil Introduces IS32FL3776 Matrix LED Driver for Intelligent Signal Displays

MILPITAS, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Lumissil Microsystems today announced the IS32FL3776 matrix…

1 hour ago

Fushi Fynix and PlayMade Honored at MARKies Awards Singapore 2026 with Two Bronze Wins

SINGAPORE, May 18, 2026 (GLOBE NEWSWIRE) -- The MARKies Awards Singapore 2026, one of the…

1 hour ago

31/2026Trifork Group: Weekly report on share buyback

Schindellegi, Switzerland – 18 May 2026 Trifork Group AGCompany announcement no. 31/2026 Weekly report on…

1 hour ago

AVITA Medical to Host Investor Webinar Briefing

May 17, 2026 18:00 ET  | Source: AVITA Medical VALENCIA, Calif., May 17, 2026 (GLOBE…

6 hours ago

Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreichs Ataxia on Monday, May 18, 2026

May 17, 2026 16:00 ET  | Source: Design Therapeutics, Inc. CARLSBAD, Calif., May 17, 2026…

6 hours ago

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto in metastatic hormone-sensitive prostate cancer

More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI…

6 hours ago